Takeda And Pfizer Sign A Co-Promotion Deal To Market Actos In China
This article was originally published in PharmAsia News
Executive Summary
Facing a looming patent cliff, Japan's Takeda made good on a pledge to dive into emerging markets by signing a co-promotion deal with Pfizer to market its type 2 Actos diabetes drug in China
You may also be interested in...
Takeda, Sanofi Team Up To Explore DPP-4 Market In China
Takeda will partner with Sanofi to co-promote its DPP-4 inhibitor Nesina, which is expected to be approved in China this year.
Takeda, Sanofi Team Up To Explore DPP-4 Market In China
Takeda will partner with Sanofi to co-promote its DPP-4 inhibitor Nesina, which is expected to be approved in China this year.
Takeda Buys Out Chinese Venture, Gains Flexibility In Decision-making For Commercial Expansion
TOKYO - Takeda currently posts only limited sales in China, but the company hopes that the full acquisition of its Chinese joint venture Tianjin Takeda will give the company more flexibility and speed in making business decisions to expand its presence in China